TY - STD TI - FDA: Orphan Drug Act. https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm2005643.htm" (1983). Accessed 6 March 2018. UR - https://www.fda.gov/ForConsumers/ConsumerUpdates/ucm2005643.htm ID - ref1 ER - TY - STD TI - EC: Regulation No 141/2000 of the European Parliament and of the Council on Orphan Medical Products. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf (2000). Accessed 6 March 2018. UR - https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2000_141_cons-2009-07/reg_2000_141_cons-2009-07_en.pdf ID - ref2 ER - TY - STD TI - PMDA: The Article 77–2 of the Pharmaceutical Affairs Law. https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/05.pdf (1985). Accessed 6 March 2018. UR - https://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/dl/05.pdf ID - ref3 ER - TY - STD TI - FDA: Orphan Drug Designations and Approvals. https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ (2018). Accessed 6 March 2018. UR - https://www.accessdata.fda.gov/scripts/opdlisting/oopd/ ID - ref4 ER - TY - STD TI - EMA: European public assessment reports. http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 (2016). Accessed 6 March 2018. UR - http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/landing/epar_search.jsp&mid=WC0b01ac058001d124 ID - ref5 ER - TY - STD TI - Ministry of Health, Labour and Welfare: Pharmaceuticals and Medical Devices. http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html (2009). Accessed 5 Sep 2016. UR - http://www.mhlw.go.jp/english/policy/health-medical/pharmaceuticals/orphan_drug.html ID - ref6 ER - TY - JOUR AU - Joppi, R. AU - Bertele, V. AU - Garattini, S. PY - 2006 DA - 2006// TI - Orphan drug development is progressing too slowly JO - Br J Clin Pharmacol VL - 61 UR - https://doi.org/10.1111/j.1365-2125.2006.02579.x DO - 10.1111/j.1365-2125.2006.02579.x ID - Joppi2006 ER - TY - JOUR AU - Putzeist, M. AU - Mantel-Teeuwisse, A. K. AU - Wied, C. C. G. AU - Hoes, A. W. AU - Leufkens, H. G. M. AU - de Vrueh, R. L. A. PY - 2013 DA - 2013// TI - Drug development for exceptionally rare metabolic diseases: challenging but not impossible JO - Orphanet J Rare Dis. VL - 8 UR - https://doi.org/10.1186/1750-1172-8-179 DO - 10.1186/1750-1172-8-179 ID - Putzeist2013 ER - TY - STD TI - EORTC: Clinical Trials Database. http://www.eortc.org/clinical-trials/ (2016). Accessed 6 March 2018. UR - http://www.eortc.org/clinical-trials/ ID - ref9 ER - TY - JOUR AU - Hilgers, R. -. D. AU - Roes, K. AU - Stallard, N. PY - 2016 DA - 2016// TI - IDeAl, Asterix and InSPiRe project groups. Directions for new developments on statistical design and analysis of small population group trials JO - Orphanet J Rare Dis. VL - 11 UR - https://doi.org/10.1186/s13023-016-0464-5 DO - 10.1186/s13023-016-0464-5 ID - Hilgers2016 ER - TY - JOUR AU - Heslop, E. AU - Csimma, C. AU - Straub, V. AU - McCall, J. AU - Nagaraju, K. AU - Wagner, K. R. PY - 2015 DA - 2015// TI - The TREAT-NMD advisory committee for therapeutics (TACT): an innovative de-risking model to foster orphan drug development JO - Orphanet J Rare Dis. VL - 10 UR - https://doi.org/10.1186/s13023-015-0258-1 DO - 10.1186/s13023-015-0258-1 ID - Heslop2015 ER - TY - STD TI - IRCI: About the initiative. http://www.irci.info/ (2016). Accessed 6 March 2018. UR - http://www.irci.info/ ID - ref12 ER - TY - STD TI - RDCRN: Clinical Research. https://www.rarediseasesnetwork.org/studies/ (2016). Accessed 6 March 2018. UR - https://www.rarediseasesnetwork.org/studies/ ID - ref13 ER - TY - JOUR AU - Dawkins, H. J. S. AU - Draghia-Akli, R. AU - Lasko, P. AU - Lau, L. AU - Jonker, A. H. AU - Cutillo, C. PY - 2017 DA - 2017// TI - Progress in rare diseases research 2010-2016: an IRDiRC perspective JO - Clin Transl Sci VL - 11 UR - https://doi.org/10.1111/cts.12501 DO - 10.1111/cts.12501 ID - Dawkins2017 ER - TY - JOUR AU - Austin, C. P. AU - Cutillo, C. M. AU - Lau, L. P. L. AU - Jonker, A. H. AU - Rath, A. AU - Julkowska, D. PY - 2017 DA - 2017// TI - Future of rare diseases research 2017-2027: an IRDiRC perspective JO - Clin Transl Sci. VL - 11 UR - https://doi.org/10.1111/cts.12500 DO - 10.1111/cts.12500 ID - Austin2017 ER - TY - STD TI - IRDiRC: TSC recommendations. http://www.irdirc.org/wp-content/uploads/2017/10/TSC_Recommendations_Final.pdf (2015). Accessed 6 March 2018. UR - http://www.irdirc.org/wp-content/uploads/2017/10/TSC_Recommendations_Final.pdf ID - ref16 ER - TY - STD TI - IRDiRC: Small Population Clinical Trials. http://www.irdirc.org/activities/task-forces/small-population-clinical-trials/ (2015). Accessed 6 March 2018. UR - http://www.irdirc.org/activities/task-forces/small-population-clinical-trials/ ID - ref17 ER - TY - STD TI - EMA/CHMP: Guideline on clinical trials in small populations. https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-trials-small-populations_en.pdf (2006). Accessed 6 March 2018. UR - https://www.ema.europa.eu/documents/scientific-guideline/guideline-clinical-trials-small-populations_en.pdf ID - ref18 ER - TY - STD TI - FDA: Rare Diseases - Common Issues in Drug Development - Guidance for Industry. https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm458485.pdf (2015). Accessed 6 March 2018. UR - https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ucm458485.pdf ID - ref19 ER - TY - STD TI - FDA: Adaptive Design Clinical Trials for Drugs and Biologics - Guidance for Industry. http://www.fda.gov/downloads/Drugs/.../Guidances/ucm201790.pdf (2010). Accessed 6 March 2018. UR - http://www.fda.gov/downloads/Drugs/Guidances/ucm201790.pdf ID - ref20 ER - TY - STD TI - PMDA: Points to be considered by the review staff involved in the evaluation process of new drug. http://www.pmda.go.jp/files/000153830.pdf (2008). Accessed 6 March 2018. UR - http://www.pmda.go.jp/files/000153830.pdf ID - ref21 ER - TY - BOOK PY - 2008 DA - 2008// TI - Longitudinal Data Analysis PB - Hall/CRC Press CY - Boca Rhaton ID - ref22 ER - TY - BOOK PY - 2008 DA - 2008// TI - Statistical issues in drug development PB - Wiley CY - New York ID - ref23 ER - TY - BOOK PY - 2010 DA - 2010// TI - Multiple testing problems in pharmaceutical statistics PB - Chapman and Hall/CRC Press CY - Boca Rhaton ID - ref24 ER - TY - BOOK PY - 1994 DA - 1994// TI - The handbook of research synthesis PB - Sage CY - New York ID - ref25 ER - TY - JOUR AU - Augustine, E. F. AU - Adams, H. R. AU - Mink, J. W. PY - 2013 DA - 2013// TI - Clinical trials in rare disease: challenges and opportunities JO - J Child Neurol VL - 28 UR - https://doi.org/10.1177/0883073813495959 DO - 10.1177/0883073813495959 ID - Augustine2013 ER - TY - STD TI - Orphan Products Natural History Grants Program. https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/OrphanProductsNaturalHistoryGrantsProgram/default.htm (2018). Accessed 11 September 2018. UR - https://www.fda.gov/ForIndustry/DevelopingProductsforRareDiseasesConditions/OrphanProductsNaturalHistoryGrantsProgram/default.htm ID - ref27 ER - TY - JOUR AU - Odgaard-Jensen, J. AU - Vist, G. E. AU - Timmer, A. AU - Kunz, R. AU - Akl, E. A. AU - Schünemann, H. PY - 2011 DA - 2011// TI - Randomisation to protect against selection bias in healthcare trials JO - Cochrane Database Syst Rev VL - 4 ID - Odgaard-Jensen2011 ER - TY - JOUR AU - Gupta, S. AU - Faughnan, M. E. AU - Tomlinson, G. A. AU - Bayoumi, A. M. PY - 2011 DA - 2011// TI - A framework for applying unfamiliar trial designs in studies of rare diseases JO - J Clin Epidemiol VL - 64 UR - https://doi.org/10.1016/j.jclinepi.2010.12.019 DO - 10.1016/j.jclinepi.2010.12.019 ID - Gupta2011 ER - TY - BOOK AU - Wassmer, G. AU - Brannath, W. PY - 2016 DA - 2016// TI - Group sequential and confirmatory adaptive designs in clinical trials PB - Springer CY - Berlin UR - https://doi.org/10.1007/978-3-319-32562-0 DO - 10.1007/978-3-319-32562-0 ID - Wassmer2016 ER - TY - BOOK AU - DeMets, D. L. AU - Furberg, C. D. PY - 2006 DA - 2006// TI - Friedman LM (editors) PB - Springer CY - Data Monitoring in Clinical Trials. A Case Studies Approach. New York ID - DeMets2006 ER - TY - BOOK AU - Ellenberg, S. S. AU - Fleming, T. R. PY - 2002 DA - 2002// TI - DeMets DL PB - Wiley CY - Data Monitoring Committees in Clinical Trials. A Practical Perspective. Chichester ID - Ellenberg2002 ER - TY - JOUR AU - Maca, J. AU - Bhattacharya, S. AU - Dragalin, V. AU - Gallo, P. AU - Krams, M. PY - 2016 DA - 2016// TI - Adaptive seamless phase II/III designs—background, operational aspects, and examples JO - Therapeutic Innovation & Regulatory Science VL - 40 ID - Maca2016 ER - TY - JOUR AU - Cuffe, R. L. AU - Lawrence, D. AU - Stone, A. AU - Vandemeulebroecke, M. PY - 2014 DA - 2014// TI - When is a seamless study desirable? Case studies from different pharmaceutical sponsors JO - Pharm Stat VL - 13 UR - https://doi.org/10.1002/pst.1622 DO - 10.1002/pst.1622 ID - Cuffe2014 ER - TY - JOUR AU - Pocock, S. J. PY - 1977 DA - 1977// TI - Randomised clinical trials JO - Br Med J VL - 1 UR - https://doi.org/10.1136/bmj.1.6077.1661 DO - 10.1136/bmj.1.6077.1661 ID - Pocock1977 ER - TY - BOOK AU - Li, Z. PY - 2007 DA - 2007// TI - Non-randomized trial PB - Wiley Encyclopedia of Clinical Trials CY - New York UR - https://doi.org/10.1002/9780471462422.eoct306 DO - 10.1002/9780471462422.eoct306 ID - Li2007 ER - TY - JOUR AU - Mullins, C. D. AU - Vandigo, J. AU - Zheng, Z. AU - Wicks, P. PY - 2014 DA - 2014// TI - Patient-centeredness in the design of clinical trials JO - Value Health J Int Soc Pharmacoeconomics Outcomes Res VL - 17 UR - https://doi.org/10.1016/j.jval.2014.02.012 DO - 10.1016/j.jval.2014.02.012 ID - Mullins2014 ER - TY - JOUR AU - Torgerson, D. J. AU - Sibbald, B. PY - 1998 DA - 1998// TI - Understanding controlled trials. What is a patient preference trial? JO - BMJ VL - 316 UR - https://doi.org/10.1136/bmj.316.7128.360 DO - 10.1136/bmj.316.7128.360 ID - Torgerson1998 ER - TY - STD TI - Risk-management plans. https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pharmacovigilance/risk-management/risk-management-plans (2018). Accessed 6 March 2018. UR - https://www.ema.europa.eu/en/human-regulatory/marketing-authorisation/pharmacovigilance/risk-management/risk-management-plans ID - ref39 ER - TY - STD TI - Regulation (EC) No 726/2004 of the European Parliament and of the Council. https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf (2004). Accessed 6 March 2018. UR - https://ec.europa.eu/health/sites/health/files/files/eudralex/vol-1/reg_2004_726/reg_2004_726_en.pdf ID - ref40 ER - TY - JOUR AU - Woodcock, J. AU - LaVange, L. M. PY - 2017 DA - 2017// TI - Master protocols to study multiple therapies, multiple diseases, or both JO - N Engl J Med VL - 377 UR - https://doi.org/10.1056/NEJMra1510062 DO - 10.1056/NEJMra1510062 ID - Woodcock2017 ER - TY - JOUR AU - Alexander, B. M. AU - Wen, P. Y. AU - Trippa, L. AU - Reardon, D. A. AU - Yung, W. -. K. A. AU - Parmigiani, G. PY - 2013 DA - 2013// TI - Biomarker-based adaptive trials for patients with glioblastoma - lessons from I-SPY 2 JO - Neuro-Oncol VL - 15 UR - https://doi.org/10.1093/neuonc/not088 DO - 10.1093/neuonc/not088 ID - Alexander2013 ER - TY - STD TI - I-SPY: Home. https://www.ispytrials.org/ (2016). Accessed 6 March 2018. UR - https://www.ispytrials.org/ ID - ref43 ER - TY - JOUR AU - Evangelista, T. AU - Hedley, V. AU - Atalaia, A. AU - Johnson, M. AU - Lynn, S. AU - Le Cam, Y. PY - 2016 DA - 2016// TI - The context for the thematic grouping of rare diseases to facilitate the establishment of European reference networks JO - Orphanet J Rare Dis VL - 11 UR - https://doi.org/10.1186/s13023-016-0398-y DO - 10.1186/s13023-016-0398-y ID - Evangelista2016 ER - TY - STD TI - EC: European networks of reference for rare diseases. https://ec.europa.eu/health/ern_en (2016). Accessed 6 March 2018. UR - https://ec.europa.eu/health/ern_en ID - ref45 ER - TY - JOUR AU - O’Connor, D. J. AU - Hemmings, R. J. PY - 2014 DA - 2014// TI - Coping with small populations of patients in clinical trials JO - Expert Opin Orphan Drugs VL - 2 UR - https://doi.org/10.1517/21678707.2014.931221 DO - 10.1517/21678707.2014.931221 ID - O’Connor2014 ER - TY - STD TI - IDEAL: Integrated DEsign and AnaLysis of clinical trials in small population groups. http://www.ideal.rwth-aachen.de/ (2016). Accessed 6 March 2018. UR - http://www.ideal.rwth-aachen.de/ ID - ref47 ER - TY - STD TI - Asterix: Welcome to the ASTERIX project. Available from: http://www.asterix-fp7.eu/ (2018). Accessed 6 March 2018. UR - http://www.asterix-fp7.eu/ ID - ref48 ER - TY - STD TI - InSPiRe: Home. https://warwick.ac.uk/fac/sci/med/research/hscience/stats/currentprojects/inspire (2018). Accessed 6 March 2018. UR - https://warwick.ac.uk/fac/sci/med/research/hscience/stats/currentprojects/inspire ID - ref49 ER - TY - STD TI - EMA: Concept paper on extrapolation of efficacy and safety in medicine development. https://www.ema.europa.eu/documents/scientific-guideline/concept-paper-extrapolation-efficacy-safety-medicine-development_en.pdf (2012). Accessed 6 March 2018. UR - https://www.ema.europa.eu/documents/scientific-guideline/concept-paper-extrapolation-efficacy-safety-medicine-development_en.pdf ID - ref50 ER - TY - STD TI - FDA. Exposure-Response Relationships — Study Design, Data Analysis, and Regulatory Applications. https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf (2003). Accessed 11 September 2018. UR - https://www.fda.gov/downloads/drugs/guidancecomplianceregulatoryinformation/guidances/ucm072109.pdf ID - ref51 ER - TY - STD TI - EMA. Reflection paper on the use of extrapolation in the development of medicines for paediatrics. https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-use-extrapolation-development-medicines-paediatrics_en.pdf (2018). Accessed 6 March 2018. UR - https://www.ema.europa.eu/documents/scientific-guideline/reflection-paper-use-extrapolation-development-medicines-paediatrics_en.pdf ID - ref52 ER - TY - STD TI - FDA. Leveraging Existing Clinical Data for Extrapolation to Pediatric Uses of Medical Devices. https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm444591.pdf (2016). Accessed 11 September 2018. UR - https://www.fda.gov/ucm/groups/fdagov-public/@fdagov-meddev-gen/documents/document/ucm444591.pdf ID - ref53 ER -